Add-on ketamine anesthesia in electroconvulsive therapy (ECT) has been studied in depressive patients in several clinical trials with inconclusive findings. Two most recent meta-analyses reported insignificant findings with regards to the treatment effect of add-on ketamine anesthesia in ECT in depressive patients. The aim of this study is to update the current evidence and investigate the role of add-on ketamine anesthesia in ECT in depressive patients via a systematic review and meta-analysis. We performed a thorough literature search of the PubMed and ScienceDirect databases, and extracted all relevant clinical variables to compare the antidepressive outcomes between add-on ketamine anesthesia and other anesthetics in ECT. Total 16 articles with 346 patients receiving add-on ketamine anesthesia in ECT and 329 controls were recruited. We found that the antidepressive treatment effect of add-on ketamine anesthesia in ECT in depressive patients was significantly higher than that of other anesthetics (p<0.001). This significance persisted in both short-term (1-2 weeks) and moderate-term (3-4 weeks) treatment courses (all p<0.05). However, the side effect profiles and recovery time profiles were significantly worse in add-on ketamine anesthesia group than in control group. Our meta-analysis highlights the significantly higher antidepressive treatment effect of add-on ketamine in depressive patients receiving ECT compared to other anesthetics. However, clinicians need to take undesirable side effects into consideration when using add-on ketamine anesthesia in ECT in depressive patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euroneuro.2016.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.
Psychiatry Res
December 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India. Electronic address:
Aim: Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorder (MDD). Following the success of ketamine, more clinical research on NMDA antagonists is needed for a safe and long-term therapy in MDD. Hence, this study was conducted to evaluate the efficacy and safety of adjunct dextromethorphan to SSRIs in MDD.
View Article and Find Full Text PDFInflammatory cytokines, cortisol, and anhedonia in patients with treatment-resistant depression after consecutive infusions of low-dose esketamine.
Eur Arch Psychiatry Clin Neurosci
September 2024
Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, China.
Article Synopsis
- Anhedonia, a key symptom of treatment-resistant depression (TRD), indicates a major loss of interest or pleasure and often predicts poor outcomes.
- A study examined how low-dose esketamine treatments affected anhedonia, inflammatory markers, and cortisol levels in 60 TRD patients, showing improvements in both depressive symptoms and anhedonia after six treatments.
- Results revealed decreased levels of cortisol, IL-6, and TNF-α, alongside an increase in IL-4, suggesting that esketamine not only helps with anhedonia but also positively influences inflammatory markers, with cortisol levels potentially serving as a biomarker for anhedonia.
Real-world treatment patterns of patients with major depressive disorder treated with Auvelity in the United States.
J Med Econ
August 2024
Axsome Therapeutics Inc, New York, NY, USA.
Aims: Major depressive disorder (MDD) is a prevalent, chronic disorder. Auvelity (dextromethorphan-bupropion) is a novel, oral -methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved (August 2022) by the FDA for treating MDD in adults. This is the first analysis on real-world Auvelity usage in the United States.
View Article and Find Full Text PDFAn update on pharmacotherapy for trigeminal neuralgia.
Expert Rev Neurother
August 2024
Paolo Procacci Foundation, Rome, Italy.
Article Synopsis
- Trigeminal neuralgia is a rare pain condition often treated with carbamazepine or oxcarbazepine, but these older medications can have significant side effects, prompting interest in newer treatment options like third-generation anticonvulsants and migraine medications.* -
- There is limited clinical evidence supporting the use of new drugs for trigeminal neuralgia, and currently, no new medications have been specifically approved for the condition in recent years, despite their potential.* -
- Many patients manage trigeminal neuralgia with a combination of medications, which may allow lower doses of traditional treatments to minimize side effects; however, the risk of drug interactions should be carefully monitored.*
Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey).
Indian J Crit Care Med
May 2024
Division of Pediatric Critical Care, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Aim: Survey of treatment practices and adherence to pediatric status epilepticus (PSE) management guidelines in India.
Methods: This eSurvey was conducted over 35 days (15th October to 20th November 2023) and included questions related to hospital setting; antiseizure medications (ASMs); ancillary treatment; facilities available; etiology; and adherence to PSE management guidelines.
Results: A total of 170 respondents participated, majority of them were working in tertiary level hospitals (94.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!